The ENDO 2026 conference, held in June, served as a critical forum for addressing a long-standing but frequently overlooked gap in clinical endocrinology: the handoff of young survivors of pituitary tumors from pediatric specialized care to adult medical services. Kevin C. J. Yuen, MD, FRCP, FEAA, medical director of the Barrow Neurological Institute and a professor of medicine at the University of Arizona College of Medicine and the Creighton University School of Medicine, utilized his "Meet-the-Professor" session to sound an alarm regarding the "vulnerable window" that opens when a pediatric patient matures out of the children’s hospital system. This transition, Dr. Yuen argued, is not merely a change of address for medical records but a high-stakes period where the risk of losing patients to follow-up is dangerously elevated, potentially leading to irreversible health complications in adulthood.
The Biological and Psychosocial Crossroads
The transition from pediatric to adult care occurs during what Dr. Yuen characterizes as the most turbulent years of a patient’s life. Spanning from the late stages of puberty to the attainment of peak bone mass, this period involves a convergence of major developmental, psychosocial, and medical shifts. For survivors of pediatric pituitary tumors (PPTs), the stakes are significantly higher than for the average adolescent. These patients are often navigating the complexities of independent living, higher education, and entry into the workforce while simultaneously managing chronic hormonal deficiencies.
The phrase "children are not just small adults" is particularly resonant in the context of pituitary tumors. In the pediatric population, these tumors—such as craniopharyngiomas and pituitary adenomas—are frequently larger and more aggressive than those typically diagnosed in adults. Because they occur during active growth and development, PPTs can have profound effects on height, sexual maturation, fertility, and metabolic health. Furthermore, pediatric tumors are more likely to be associated with genetic syndromes, such as Multiple Endocrine Neoplasia type 1 (MEN1) or Carney complex, which require a lifetime of vigilant surveillance and complex management strategies that many general adult endocrinologists may not be accustomed to treating.
A Crisis of Continuity: Analyzing the Data
The urgency of Dr. Yuen’s message is supported by sobering data regarding treatment interruptions. During his presentation, he cited a European audit revealing that approximately 70% of patients experienced a growth hormone (GH) treatment interruption of more than two years during the transition from pediatric to adult care. This statistic is alarming because GH therapy is often misunderstood as a treatment solely for linear growth. In reality, growth hormone remains vital throughout the transition period and into adulthood for maintaining bone density, muscle mass, cardiovascular health, and overall quality of life.
When care is interrupted, the progress made during childhood can be quickly undone. A two-year gap in GH replacement can lead to decreased bone mineral density at a time when the body should be reaching its peak, increasing the risk of fractures later in life. Moreover, interruptions in the management of other axes—such as thyroid or adrenal replacement—can lead to acute medical crises or chronic fatigue, further hindering a young adult’s ability to succeed in their educational or professional pursuits.
Structural Barriers in the United States Healthcare System
While clinical needs are paramount, the transition is often derailed by systemic hurdles. In the United States, the healthcare landscape is fragmented, characterized by a complex web of private and public payers, varying institutional geographies, and strict age-based cutoffs for pediatric services. Dr. Yuen noted that insurance coverage often dictates treatment choices, forcing clinicians to opt for "second- or third-best" options when optimal, evidence-based therapies are not covered.
Geographic disparities also play a significant role. Many pediatric pituitary survivors are treated at tertiary children’s hospitals with dedicated neuroendocrine teams. However, upon reaching adulthood, they may find themselves in regions where no adult neuroendocrinologist is available. This often results in a transition to general endocrinologists who, while highly skilled, may lack the specific experience required to manage the rare and aggressive nature of PPT survivors. The physical distance between the childhood treatment center and the new adult clinic can also lead to "appointment fatigue," where patients, feeling healthy in the short term, stop seeking specialized care until symptoms become severe.
International Models of Success: Ready, Steady, Go
To address these systemic failures, Dr. Yuen highlighted frameworks developed in other healthcare systems that could serve as blueprints for improvement. One such model is the United Kingdom’s National Health Service (NHS) initiative known as the "Ready Steady Go" program. This structured pathway begins as early as age 11, introducing the concept of transition long before the actual transfer of care occurs.
The program moves through three distinct stages:
- Ready: Starting at ages 11–12, focusing on basic disease awareness.
- Steady: Mid-teens, focusing on self-management skills and understanding medications.
- Go: Late teens, preparing for the final handoff and ensuring the patient can navigate the adult system independently.
- Hello: The final stage, where the patient is successfully established within an adult care clinic.
By the time the patient reaches the "Hello" stage, they have been empowered to take ownership of their health. Dr. Yuen also pointed to the "6 Core Elements of Health Care Transition" (Got Transition 2.0), a joint effort by the American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Physicians. These elements—transition policy, tracking, readiness assessment, planning, transfer of care, and completion—provide a systematic way for U.S. institutions to monitor patients and ensure they do not fall through the cracks.
Clinical Implications of Pediatric Pituitary Tumors
The medical complexity of PPT survivors cannot be overstated. Unlike adult-onset pituitary issues, pediatric cases often involve survivors of craniopharyngiomas who suffer from hypothalamic obesity. This condition, caused by damage to the hypothalamus during tumor growth or surgical intervention, results in rapid, uncontrollable weight gain that does not respond to traditional diet and exercise.
Dr. Yuen emphasized that early intervention during the transition period is the only way to mitigate the long-term impact of hypothalamic obesity. If weight gain is not addressed in the late teens and early twenties, it sets the stage for a lifetime of metabolic syndrome, type 2 diabetes, and cardiovascular disease. Similarly, the transition period is the time to address fertility preservation and bone health. Many survivors may require assisted reproductive technologies or specific bone-building therapies that must be initiated before irreversible damage occurs.
The Role of Patient Empowerment and Multidisciplinary Teams
A recurring theme in Dr. Yuen’s session was the necessity of moving beyond a paternalistic model of medicine toward one of patient empowerment. This shift is echoed in the February joint clinical practice guidance from the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE). These guidelines stress that transition is a process, not a single event.
Effective transition requires a multidisciplinary team (MDT) that includes not just endocrinologists, but also neurosurgeons, ophthalmologists, psychologists, and fertility specialists. Psychological support is particularly crucial; survivors of brain tumors often face neurocognitive challenges and psychiatric disorders that can impair their ability to manage a complex medical regimen. A transition coordinator or a specialized nurse can often act as the "glue" that holds these disparate pieces of care together, ensuring that the patient feels supported rather than abandoned.
Strategies for Clinicians: Starting the Conversation Early
The onus for initiating the transition process primarily falls on pediatricians and pediatric endocrinologists, as they are the first point of contact for these families. Dr. Yuen’s advice to his colleagues was clear: "Plant the seed early." By discussing the lifelong nature of endocrine treatment when the child is still young, clinicians can normalize the idea of moving to adult care, reducing the anxiety associated with leaving a familiar pediatric environment.
He suggested that adult endocrinologists should be introduced to the patient and their family well before the final transfer. Joint clinics, where the pediatric and adult specialists see the patient together, are considered the "gold standard" for transition, though they remain difficult to implement in many U.S. hospital structures due to billing and administrative hurdles.
Future Outlook and Broader Implications
The robust attendance and high level of engagement at the ENDO 2026 session indicate a growing recognition within the medical community that the transition of care is a critical quality-of-life issue. As medical advancements allow more children to survive pituitary tumors, the population of adult survivors continues to grow, necessitating a more robust infrastructure to support them.
Dr. Yuen’s presentation served as both a warning and a call to action. The consequences of failing these patients during their "vulnerable window" are measured in lost potential and increased morbidity. However, by adopting structured frameworks, advocating for insurance reform to cover essential transition services, and fostering a culture of patient empowerment, the endocrine community can bridge the gap.
In his concluding remarks, Dr. Yuen remained optimistic, noting that while there is no "one-size-fits-all" solution for the diverse healthcare landscape of the United States, the application of universal principles—early intervention, multidisciplinary care, and long-term surveillance—can significantly improve outcomes. The goal is to ensure that a child who survives a pituitary tumor does not just reach adulthood, but thrives within it, equipped with the medical support and personal agency necessary to lead a healthy, productive life.
